Planning for Cell & Gene Therapy Commercialization

Planning for Cell & Gene Therapy Commercialization   
A panel discussion with:
 Matt Booth, SVP Global Therapy Lead, ApotheCom, An Inizio Company
Ben Beckley, President, Evoke Mind + Matter, An Inizio Company
Dean McAlister, EVP, Inizio Biotech
Greg Christianson, Principal, Nuvera, An Inizio Company
Rita Johnson-Greene, COO, Alliance for Regenerative Medicine (ARM)
Bringing cell & gene therapies to market is no easy feat. The many technicalities involved in running trials, scaling manufacturing capabilities, market access and launch drives up end-to-end costs, meaning patients are often faced with a complex, long and expensive road to treatment.
With the aim to bring CGT’s to as many patients as possible, panellists discuss the early-commercial planning factors facing CGT companies today and tried-and-tested solutions.
The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.
Subscribe to our channel for more videos.
Follow us on Twitter: / lsxleaders
Visit us at www.lsxleaders.com